JAZZ Stock Forecast: Jazz Pharmaceuticals Plc Price Predictions for 2026-2027

Last close, 20 Nov 2026
$231
−2.35% on the day

The 22 Wall Street analysts covering Jazz Pharmaceuticals Plc hold a median 12-month price target of $300 — +29.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$14.8B
Ticker Nerd rank
95/ 100
Median analyst target
$300
Analysts covering
22
Revenue$1.2B+15.5% y/y
Operating income$325.2M
Net income$192.8M
Free cash flow$243.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.4%
1M
+8.0%
YTD
+35.8%
1Y
+31.4%
From 52W high
−11.7%
From 52W low
+44.1%
$160
$262
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Jazz Pharmaceuticals Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
95/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
98
Momentum
94
Growth
93
Accruals
90
Quality
82
Revisions
61
Issuance
34

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

JAZZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JAZZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350Jan 26Apr 26Jul 26Oct 26JAZZHigh $330Median $300Low $220

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
20
Buy
2
Hold
0
Sell
$220
Low
$300
Median
$330
High

The green dot is the last close — the median target sits +29.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 16 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
13 Nov 2026Morgan StanleyMaintainsOverweight$319 → $324
12 Nov 2026Piper SandlerMaintainsOverweight$310 → $330
3 Nov 2026BarclaysMaintainsOverweight$271 → $275
3 Nov 2026JP MorganMaintainsOverweight$300 → $310
3 Nov 2026Morgan StanleyMaintainsOverweight$314 → $319
3 Nov 2026RBC CapitalMaintainsOutperform$296 → $305
28 Oct 2026JP MorganMaintainsOverweight$276 → $300
21 Oct 2026Morgan StanleyMaintainsOverweight$322 → $314
8 Oct 2026RBC CapitalMaintainsOutperform$299 → $296
7 Oct 2026Truist SecuritiesMaintainsBuy$281 → $286
30 Sept 2026CitigroupInitiatesBuy$325
24 Sept 2026Goldman SachsReinstatesBuy$337
11 Sept 2026UBSMaintainsBuy$315 → $337
10 Sept 2026BarclaysMaintainsOverweight$270 → $271
26 Aug 2026Deutsche BankMaintainsBuy$287 → $300
26 Aug 2026Morgan StanleyMaintainsOverweight$283 → $322
26 Aug 2026NeedhamMaintainsBuy$292 → $310
26 Aug 2026Truist SecuritiesMaintainsBuy$264 → $281
11 Aug 2026Morgan StanleyMaintainsOverweight$280 → $283
4 Aug 2026BairdMaintainsOutperform$252 → $280

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for JAZZ.

Market Radar

This page is one stock. Monday covers all of them.

JAZZ appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

JAZZ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Jazz Pharmaceuticals Plc returned +31.4% against +6.9% for the S&P 500, dividends included.

JAZZ vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26JAZZS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

JAZZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−40.3%
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
68.1×

Cheaper than 12% of US stocks

Price / sales
3.1×

Cheaper than 35% of US stocks

Price / book
3.5×

Cheaper than 26% of US stocks

EV / EBITDA
8.7×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
90.4%

Higher than 96% of US stocks

Operating margin
27.4%

Higher than 86% of US stocks

Net margin
—
Returns & dividend
Return on equity
5.1%

Higher than 52% of US stocks

Return on assets
6.9%

Higher than 84% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Jazz Pharmaceuticals Plc has a market value of $14.8B and an enterprise value of $17.6B.

  • Revenue in the twelve months to 30 June 2026: $4.6B. The latest quarter grew 15.5% year on year.

  • Net income over the same four quarters: $940.8M, a 20.4% net margin.

  • Diluted earnings per share, trailing twelve months: $14.50.

  • Free cash flow in the twelve months to 30 June 2026: $1.3B.

  • Shares outstanding: 64.8M.

  • Trailing P/E: 68.1×; forward P/E: 8.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Jazz Pharmaceuticals Plc employs 2,890 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

JAZZ and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JAZZJazz Pharmaceuticals Plc$14.8B95
BBIOBridgeBio Pharma, Inc.$14.7B80
EXELExelixis, Inc.$15.8B100
ASNDAscendis Pharma A/S$16.6B93
BMRNBioMarin Pharmaceutical, Inc.$11.7B51
TECHBio-Techne Corp.$11.3B96
ALNYAlnylam Pharmaceuticals, Inc.$19.3B58

Take a look at JAZZ’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Jazz Pharmaceuticals Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about JAZZ

What is the JAZZ stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Jazz Pharmaceuticals Plc have a median 12-month price target of $300, with estimates ranging from $220 to $330. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JAZZ stock a buy right now?

Of the 22 analysts covering Jazz Pharmaceuticals Plc, 20 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jazz Pharmaceuticals Plc 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JAZZ?

As at 21 Nov 2026, Jazz Pharmaceuticals Plc ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will JAZZ stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +29.9% from the last close, and Ticker Nerd's factor model ranks Jazz Pharmaceuticals Plc 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JAZZ stock forecast for 2030?

No analyst covering Jazz Pharmaceuticals Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JAZZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $220 to $330 over the next 12 months.

How has JAZZ stock performed over the past year?

Jazz Pharmaceuticals Plc returned +31.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Jazz Pharmaceuticals Plc do?

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options.

Company

About Jazz Pharmaceuticals Plc.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options. Jazz Pharmaceuticals plc works across the United States, Europe, and other international markets, serving healthcare providers, hospitals, and patients through prescription medicines and specialty care solutions. The company emphasizes rare disease and oncology medicines, making it an important participant in the global specialty pharmaceutical market. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc maintains a focused business model centered on identifying, developing, and commercializing targeted therapies for complex medical needs.

CEO Ms. Renee D. Gala · 2,890 employees · Ireland · https://www.jazzpharma.com